The medicinal chemistry of the DATA and DAPY series of HIV-1 non-nucleoside reverse transcriptase inhibitors (NNRTIs)

Advances in Antiviral Drug Design

Volumn 5, Issue , 2007, Pages 213-242

  Heeres, Jan ^a   Lewi, Paul J ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANIMALIA; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 40449097507     PISSN: 10758593     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S1075-8593(06)05006-4     Document Type: Review

References (26)

1. Andries K., Azijn H., Thielemans T., Ludovici D., Kukla M., Heeres J., Janssen P., De Corte B., Vingerhoets J., Pauwels R., and de Béthune M.-P. TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 48 (2004) 4680-4686
2. E. Arnold, K. Das, A.D. Clark Jr., S.H. Hughes, X-ray crystal structure of R147681 (TMC120) complexed with HIV-1 reverse transcriptase, Personal communication, CABM Rutgers University, New Jersey, 1999
3. Das K., Clark Jr. A.D., Lewi P.J., Heeres J., de Jonge M.R., Koymans L.M.H., Vinkers H.M., Daeyaert F., Ludovici D.W., Kukla M.J., De Corte B., Kavash R.W., Ho C.Y., Ye H., Lichtenstein M.A., Andries K., Pauwels R., de Bethune M.-P., Boyer P.L., Clark P., Hughes S.H., and Janssen P.A.J. Roles of conformational and positional adaptability in structure-based design of TMC125- R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants. J. Med. Chem. 47 (2004) 2550-2560
4. De Corte B.L. From 4,5,6,7-tetrahydro-5-methylimidazo[4,5,1- j k](1,4)benzodiazepin-2-(1H)-one (TIBO) to etravirine (TMC125): Fifteen years of research on non-nucleoside inhibitors of HIV-1 reverse transcriptase. J. Med. Chem. 48 (2005) 1689-1696
5. Di Fabio S., Van Roey J., Giannini G., van den Mooter G., Spada M., Binelli A., Pirillo M.F., Germinario E., Belardelli F., de Béthune M.-P., and Vella S. Inhibition of vaginal transmission of HIV-1 in hu-SCID mice by the non-nucleoside reverse transcriptase inhibitor TMC120 in a gel formulation. AIDS 17 (2003) 1597-1604
6. Ding J., Das K., Tantillo C., Zhang W., Clark Jr. A.D., Pauwels R., Moereels H., Koymans L., Janssen P.A.J., Smith Jr. R.H., Kroeger Smith M.B., Koepke M., Michejda C.J., Hughes S.H., and Arnold E. Structure of HIV-1 reverse transcriptase in a complex with the non-nucleoside inhibitor α-APA R95845 at 2.8 Å resolution. Structure 3 (1995) 365-379
7. Ding J., Das K., Moereels H., Koymans L., Andries K., Janssen P.A.J., Hughes S.H., and Arnold E. Structure of HIV-1 RT/TIBO R86183 complex reveals similarity in the binding of diverse non-nucleoside inhibitors. Nature Struct. Biol. 2 (1995) 407-415
8. Gazzard B.G., Pozniak A.L., Rosenbaum W., Yeni G.P., Staszewski S., Arasteh K., De Dier K., Peeters M., Woodfall B., Stebbing J., and van 't Klooster G.A. An open-label assessment of TMC 125, a new, next-generation NNRTI, for 7 days in HIV-1 infected individuals with NNRTI resistance. AIDS 17 (2003) F49-F54
9. F. Goebel, A. Yakovlev, A. Pozniak, E. Vinogradova, P. Lewi, G. Boogaerts, R. Hoetelmans, M.-P. de Béthune, M. Peeters, B. Woodfall, TMC278: Potent anti-HIV activity in antiretroviral therapy-naïve patients. Abstract 160. Conf. Retrovirus Opportun. Infect., Boston, 22-25 February 2005
10. Gruzdev B., Rakhmanova A., Doubovskaya E., Yakovlev A., Peeters M., Rinehart A., de Dier K., Baede-Van Dijk P., Parys W., and van 't Klooster G.A. A randomized, double-blind, placebo-controlled trial of TMC125 as 7-day mono-therapy in antiretroviral naïve, HIV-1 infected subjects. AIDS 17 (2003) 2487-2494
11. Guillemont J., Pasquier E., Palandjian P., Vernier D., Gaurrand S., Lewi P.J., Heeres J., de Jonge M.R., Koymans L.M.H., Daeyaert F.F.D., Vinkers M.H., Arnold E., Das K., Pauwels R., Andries K., de Béthune M.-P., Bettens E., Hertogs K., Wigerinck P., Timmerman P., and Janssen P.A.J. Synthesis of novel diarylpyrimidine analogues and their antiviral activity against human immunodeficiency virus type 1. J. Med. Chem. 48 (2005) 2072-2079
12. Y. Ivanov, A. Lisitsa, I. Karuzina, A.I. Archakov, Atomic force microscopy of aggregates of R278474 (TMC278), Personal communication, Institute of Biomedical Chemistry, Russ. Acad. Sc., Moscow, 2004
13. Janssen P.A.J., Lewi P.J., Arnold E., Daeyaert F., de Jonge M., Heeres J., Koymans L., Vinkers M., Guillemont J., Pasquier E., Kukla M., Ludovici D., Andries K., de Béthune M.-P., Pauwels R., Das K., Clark Jr. A.D., Frenkel Y.V., Hughes S.H., Medaer B., De Knaep F., Bohets H., De Clerck F., Lampo A., Williams P., and Stoffels P. In search of a novel anti-HIV drug: Multidisciplinary coordination in the discovery of 4-[[4-[[4-(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile (R278474, Rilpivirine). J. Med. Chem. 48 (2005) 1901-1909
14. Kohlstaedt L.A., Wang J., Friedman J.M., Rice P.A., and Steitz T.A. Crystal structure at 3.5 Å resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science 256 (1992) 1783-1790
15. Kukla M.J., Breslin H.J., Diamond C.J., Grous P.P., Ho C.Y., Miranda M., Rodgers J.D., Sherrill R.G., De Clercq E., Pauwels R., Andries K., Moens L.J., Janssen M.A.C., and Janssen P.A.J. Synthesis and anti-HIV-1 activity of 4,5,6,7-tetrahydro-5-methylimidazo[4,5,1- j k][1,4]benzodiazepin-2-(1H)-one (TIBO) derivatives. 2. J. Med. Chem. 34 (1991) 3187-3197
16. Kukla M.J., Breslin H.J., Pauwels R., Fedde C.L., Miranda M., Scott M.K., Sherrill R.G., Raeymaekers A., Van Gelder J., Andries K., Janssen K., Janssen M.A.C., De Clercq E., and Janssen P.A.J. Synthesis and anti-HIV-1 activity of 4,5,6,7-tetrahydro-5-methylimidazo [4,5,1- j k] [1,4] benzodiazepin-2-(1H)-one (TIBO) derivatives. J. Med. Chem. 34 (1991) 746-751
17. Lewi P.J., de Jonge M., Daeyaert F., Koymans L., Vinkers M., Heeres J., Janssen P.A.J., Arnold E., Das K., Clark Jr. A.D., Hughes S.H., Boyer P.L., De Bethune M.P., Pauwels R., Andries K., Kukla M., Ludovici D., De Corte B., Kavash R., and Ho C. On the detection of multiple-binding modes of ligands to proteins, from biological, structural, and modeling data. J. Comput. Aided Mol. Des. 17 (2003) 129-134
18. Lewi P., Arnold E., Andries K., Bohets H., Borghys H., Clark Jr. A.D., Daeyaert F., Das K., de Béthune M.-P., de Jonge M., Heeres J., Koymans L., Leempoels J., Peeters J., Timmerman P., Van den Broeck W., Vanhoutte F., van 't Klooster G., Vinkers M., Volovik Y., and Janssen P.A.J. Correlations between factors determining the pharmacokinetics and antiviral activity of HIV-1 nonnucleoside reverse transcriptase inhibitors of the diaryltriazine and diarylpyrimidine classes of compounds. Drugs R & D 5 (2004) 245-257
19. Ludovici D.W., Kukla M.J., Grous P.G., Krishnan S., Andries K., de Béthune M.-P., Azijn H., Pauwels R., De Clercq E., Arnold E., and Janssen P.A.J. Evolution of anti-HIV drug candidates. Part 1: From α-anilinophenylacetamide (α-APA) to imidoyl thiourea (ITU). Bioorg. Med. Chem. Lett. 11 (2001) 2225-2228
20. Ludovici D.W., Kavash R.W., Kukla M.J., Ho C.Y., Ye H., De Corte B.L., Andries K., de Béthune M.-P., Azijn H., Pauwels R., Moereels H.E.L., Heeres J., Koymans L.M.H., de Jonge M.R., Van Aken K.J.A., Daeyaert F.F.D., Lewi P.J., Das K., Arnold E., and Janssen P.A.J. Evolution of anti-HIV drug candidates. Part 2: Diaryltriazine (DATA) analogues. Bioorg. Med. Chem. Lett. 11 (2001) 2229-2234
21. Ludovici D.W., De Corte B.L., Kukla M.J., Ye H., Ho C.Y., Lichtenstein M.A., Kavash R.W., Andries K., de Béthune M.-P., Azijn H., Pauwels R., Lewi P.J., Heeres J., Koymans L.M.H., de Jonge M.R., Van Aken K.J.A., Daeyaert F.F.D., Das K., Arnold E., and Janssen P.A.J. Evolution of anti-HIV drug candidates. Part 3: Diarylpyrimidine (DAPY) analogues. Bioorg. Med. Chem. Lett. 11 (2001) 2235-2239
22. Pauwels R., Andries K., Desmyter J., Schols D., Kukla M.J., Breslin H.J., Raeymaekers A., Van Gelder J., Woestenborghs R., Heykants J., Schellekens K., Janssen M.A.C., De Clercq E., and Janssen P.A.J. Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives. Nature 343 (1990) 470-474
23. Pauwels R., Andries K., Debyser Z., Van Daele P., Schols D., Stoffels P., De Vreeze K., Woestenborghs R., Vandamme A.M., Janssen C.G.M., Anne J., Cauwenbergh G., Desmyter J., Heykants J., Janssen M.A.C., De Clercq E., and Janssen P.A.J. Potent and highly selective human immunodeficiency virus type 1 (HIV-1) inhibition by a series of α-anilinophenylacetamide derivatives targeted at HIV-1 reverse transcriptase. Proc. Natl. Acad. Sci. USA 90 (1993) 1711-1715
24. Van Herrewege Y., Vanham G., Michiels J., Fransen K., Kestens L., Andries K., Janssen P., and Lewi P. A series of diaryltriazines and diarylpyrimidines are highly potent nonnucleoside reverse transcriptase inhibitors with possible applications as microbicides. Antimicrob. Agents Chemother. 48 (2004) 3684-3689
25. Volovik Frenkel Y., Clark Jr. A.D., Das K., Wang Y.-H., Lewi P.J., Janssen P.A.J., and Arnold E. Concentration and pH dependent aggregation of hydrophobic drug molecules and relevance to oral bioavailability. J. Med. Chem. 48 (2005) 1974-1983
26. Y.-H. Wang, Y. Volovik Frenkel, E. Arnold, Electron microscopy of aggregates of R147681 (TMC120), Personal communication, CABM Rutgers Univ. and Univ. Med. Dentistry, New Jersey, 2003